Highlight box
Key findings
• Pleurodesis using talc or minocycline might be the treatment option against malignant pleural effusion (MPE) secondary to lung cancer with interstitial lung disease (ILD).
What is known and what is new?
• The efficacy rate of pleurodesis with talc and minocycline is about 70%. Acute respiratory distress syndrome (ARDS) after pleurodesis with talc is a concern. The partially expanded lung before pleurodesis is known as the predictor of pleurodesis failure. The efficacy and safety of pleurodesis against MPE complicated with ILD have not been elucidated.
• In this study, excluding the cases of partially expanded lung, the efficacy rate of pleurodesis against MPE complicated with ILD was comparable to that of previous reports. Presenting ground glass opacity and consolidation treated with systemic prednisolone within 6 months before pleurodesis might be the risk factor for developing ARDS.
What is the implication, and what should change now?
• Pleurodesis against MPE might be the therapeutic option for patients complicated with ILD. However, two cases of ARDS were observed in the patients administered systemic prednisolone against ILD within 6 months before pleurodesis. The clinicians should carefully consider the indication for pleurodesis.
Publication: Iso H, Miyanaga A, Sato Y, Shirakura Y, Shinbu K, Inoue T, Nagano A, Misawa K, Tozuka T, Murata A, Higa K, Takeuchi S, Matsumoto M, Kamio K, Kasahara K, Seike M. Efficacy and safety of pleurodesis for lung cancer patients with interstitial lung disease. J Thorac Dis 2025;17(2):687-694. doi: 10.21037/jtd-24-1541
Journal
Journal of Thoracic Disease
Method of Research
Observational study
Subject of Research
People
Article Title
Efficacy and safety of pleurodesis for lung cancer patients with interstitial lung disease
Article Publication Date
27-Feb-2025
COI Statement
All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1541/coif). Akihiko Miyanaga received these horaria from AstraZeneca, Nippon Kayaku, Merck, Kyowa Kirin, and Pfizer. T.T. has received honoraria from AstraZeneca and Chugai Pharmaceutical. Masaru Matsumoto has received honoraria from Astra Zeneca, Chugai Pharmaceutical, Taiho Pharmaceutical, and Ono Pharmaceutical. Kazuo Kasahara has received honoraria from MSD, AstraZeneca, Chugai Pharmaceutical, Bristol-Myers Squib, Taiho Pharmaceutical, Pfizer, Eli Lilly, and Boehringer Ingelheim, and has received consulting fees from Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly, AstraZeneca, and has patents with Boehringer Ingelheim serves on boards for AstraZeneca and Eli Lilly. M.S. had grants or contracts: Taiho Pharmaceutica, Chugai Pharmaceutical, Eli Lilly, Nippon Kayaku, and Kyowa Hakko Kirin, as well as honoraria from AstraZeneca, MSD K.K, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Pfizer, Novartis, Takeda Pharmaceutical, Kyowa Hakko Kirin, Nippon Kayaku, Daiichi-Sankyo Company, Merck Biopharma, and Amgen Inc. The other authors have no conflicts of interest to declare.